Marshall Wace’s Aldeyra Therapeutics ALDX Stock Holding History

Marshall Wace’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$219K	Buy	+129,693	New	+$568K	﹤0.01%	2757
2025 Q4	–	Sell	-160,213	Closed	-$836K	–	2921
2025 Q3	$836K	Buy	+160,213	New	+$835K	﹤0.01%	2018
2023 Q3	–	Sell	-183,337	Closed	-$1.54M	–	2151
2023 Q2	$1.54M	Buy	183,337 +106,232	+138%	+$1.05M	﹤0.01%	1527
2023 Q1	$766K	Sell	77,105 -245,476	-76%	-$1.74M	﹤0.01%	1928
2022 Q4	$2.25M	Buy	322,581 +122,418	+61%	+$700K	0.01%	1672
2022 Q3	$1.07M	Buy	200,163 +122,482	+158%	+$735K	﹤0.01%	2371
2022 Q2	$309K	Buy	+77,681	New	+$267K	﹤0.01%	3014
2018 Q4	–	Sell	-15,835	Closed	-$219K	–	1567
2018 Q3	$219K	Buy	+15,835	New	+$128K	﹤0.01%	1057

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's ALDX Position: Q1 2026 in Review

Marshall Wace opened a new position in Aldeyra Therapeutics (ALDX) in Q1 2026: 129,693 shares worth $219K. The stake represents ﹤0.01% of the portfolio and ranks #2757 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ALDX as recently as Q3 2025.

Marshall Wace first reported a position in ALDX in Q3 2018 and has held it in 8 quarters since. The position peaked at $2.25M in Q4 2022. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Marshall Wace held 129,693 shares of Aldeyra Therapeutics worth $219K as of Q1 2026.
Aldeyra Therapeutics was a new Marshall Wace position in Q1 2026.
Aldeyra Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2757 holding.
Marshall Wace first reported a position in Aldeyra Therapeutics in Q3 2018 and has held it in 8 quarters since.
Marshall Wace's Aldeyra Therapeutics position peaked at $2.25M in Q4 2022.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.